153 related articles for article (PubMed ID: 8914087)
1. Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: a comparison with L-Dopa treatment.
Benazzouz A; Boraud T; Féger J; Burbaud P; Bioulac B; Gross C
Mov Disord; 1996 Nov; 11(6):627-32. PubMed ID: 8914087
[TBL] [Abstract][Full Text] [Related]
2. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate.
Aziz TZ; Peggs D; Sambrook MA; Crossman AR
Mov Disord; 1991; 6(4):288-92. PubMed ID: 1758446
[TBL] [Abstract][Full Text] [Related]
3. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Pearce RK; Banerji T; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
[TBL] [Abstract][Full Text] [Related]
4. Abnormal involuntary movements induced by subthalamic nucleus stimulation in parkinsonian patients.
Limousin P; Pollak P; Hoffmann D; Benazzouz A; Perret JE; Benabid AL
Mov Disord; 1996 May; 11(3):231-5. PubMed ID: 8723137
[TBL] [Abstract][Full Text] [Related]
5. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
[TBL] [Abstract][Full Text] [Related]
6. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
7. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism.
Wichmann T; Bergman H; DeLong MR
J Neurophysiol; 1994 Aug; 72(2):521-30. PubMed ID: 7983516
[TBL] [Abstract][Full Text] [Related]
8. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
[TBL] [Abstract][Full Text] [Related]
9. Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission.
Gubellini P; Eusebio A; Oueslati A; Melon C; Kerkerian-Le Goff L; Salin P
Eur J Neurosci; 2006 Sep; 24(6):1802-14. PubMed ID: 17004943
[TBL] [Abstract][Full Text] [Related]
10. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys.
Benazzouz A; Gross C; Féger J; Boraud T; Bioulac B
Eur J Neurosci; 1993 Apr; 5(4):382-9. PubMed ID: 8261116
[TBL] [Abstract][Full Text] [Related]
11. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM
Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221
[TBL] [Abstract][Full Text] [Related]
12. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys.
Schneider JS; Pope-Coleman A; Van Velson M; Menzaghi F; Lloyd GK
Mov Disord; 1998 Jul; 13(4):637-42. PubMed ID: 9686767
[TBL] [Abstract][Full Text] [Related]
13. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Blanchet PJ; Grondin R; Bédard PJ
Mov Disord; 1996 Jan; 11(1):91-4. PubMed ID: 8771074
[TBL] [Abstract][Full Text] [Related]
14. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
[TBL] [Abstract][Full Text] [Related]
15. [Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
Chen S
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1992 Feb; 25(1):50-2, 64. PubMed ID: 1591961
[TBL] [Abstract][Full Text] [Related]
16. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiology of parkinsonian motor abnormalities.
Wichmann T; DeLong MR
Adv Neurol; 1993; 60():53-61. PubMed ID: 8420185
[No Abstract] [Full Text] [Related]
18. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
19. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
Kuoppamäki M; Al-Barghouthy G; Jackson M; Smith L; Zeng BY; Quinn N; Jenner P
Mov Disord; 2002 Nov; 17(6):1312-7. PubMed ID: 12465074
[TBL] [Abstract][Full Text] [Related]
20. Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease.
Devos D; Labyt E; Derambure P; Bourriez JL; Cassim F; Reyns N; Blond S; Guieu JD; Destée A; Defebvre L
Brain; 2004 Feb; 127(Pt 2):408-19. PubMed ID: 14691060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
